权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

An In Vivo Voltammetric Serotonin Biomarker for Antidepressant Efficacy

抗抑郁功效的体内伏安血清素生物标志物

基本信息

批准号：
9026128
负责人：
Parastoo Hashemi
金额：
$ 34.06万
依托单位：
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-15 至 2021-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9026128
关键词：
Adsorption Adverse effects Affinity Agreement Animal Behavior Animal Model Animals Antidepressive Agents Autoreceptors Behavioral Biological Markers Brain Brain region Chemicals Chemistry Computer Simulation Consensus Data Depressed mood Development Disease Economic Burden Economics Electrochemistry Electrodes Escitalopram Fluoxetine Fluvoxamine Goals Hippocampus (Brain)Individual Life Literature Mathematics Measurement Measures Mental Depression Mental disorders Methods Mind Mission Modeling Monitor Mus Pattern Pharmaceutical Preparations Preclinical Drug Evaluation Process Property Public Health Reporting Research Research Personnel Resolution Resources Scanning Selective Serotonin Reuptake Inhibitor Serotonergic System Serotonin Signal Transduction Societies Staging Substantia nigra structure Techniques Technology Testing Therapeutic Treatment Efficacy Work analytical tool antidepressant effect brain behavior burden of illness carbon fiber clinical efficacy desensitization drug development drug discovery extracellular improved in vivo in vivo Model innovation interdisciplinary approach interest mathematical model mouse model neuropsychiatric disorder novel novel therapeutics pre-clinical predict clinical outcome public health relevance response reuptake screening serotonin transporter therapy outcome tool uptake

项目摘要

DESCRIPTION (provided by applicant): There are no reliable screening tools that predict clinical outcome in the preclinical stages of antidepressant drug development, this is an analytical shortcoming that has led to a recent decline in resources for antidepressant drug discovery. Given that by 2030 depression is predicted to become one of the leading global disease burdens, it is particularly pertinent to create analytical tools that accurately screen the efficacy of antidepressant therapies. The long-term goal of the proposed research is to understand how antidepressants modulate the serotonin system thereby establishing a serotonin biomarker for early stage drug screening. The objectives of this proposal are to a) enable precise measurements of serotonin's basal and evoked levels in vivo in the mouse hippocampus, b) establish the mechanisms that control extracellular serotonin in healthy and depressed mice and c) correlate chemical patterns in the way that different antidepressants modulate serotonin to clinical efficacy. Our preliminary data strongly support our proposed objectives. We have made significant progress in making the first measurements of basal and evoked serotonin in the hippocampus with fast scan cyclic voltammetry and a novel method, fast scan controlled adsorption voltammetry. Furthermore, we measured basal and evoked serotonin in depressed mouse models and found that serotonin levels are higher in depressed mice, proposing a mechanism for this finding via computational modeling. Finally, we mathematically correlated serotonin's extracellular response after different antidepressants to clinical efficacy and made an accurate prediction of efficacy for a known compound. This preliminary data allows us to make the central hypothesis that antidepressants influence extracellular levels of serotonin via different mechanisms, giving rise to unique "serotonin signatures", which can be used to predict their likely degree of clinical efficacy. The rationale i that by correlating chemical serotonin patterns to clinical efficacy, a `serotonin biomarker' can identify the most clinically efficacious compounds. We take an interdisciplinary approach to test the central hypothesis via three specific aims: 1. Perform Fundamental FSCV Measurements of Serotonin's Ambient and Evoked Chemistry in the Hippocampus. 2. Establish Mechanisms Regulating In Vivo Extracellular Serotonin Levels in Healthy and Depressed Animal Models. 3. Correlate the Ability of Antidepressants to Influence Extracellular Serotonin (Ambient and Evoked) to Clinical Efficacy. The approach is innovative because it brings together advanced analytical techniques, mathematics and animal behavior to tackle important analytical challenges. The proposed research is significant because it can ultimately provide a means to screen antidepressants via a serotonin biomarker. Having an early stage screening tool is a powerful impetus for drug discoverers to resume their efforts in improving antidepressant therapies, benefiting individuals, society and the economy. The research will also have impact on a much broader research agenda. Serotonin measurement tools and working models of in vivo serotonin mechanisms can open and advance entire new lines of serotonin-related research.